Novo Nordisk

NVO

Market cap $166B

Novo Nordisk is repriced as if its fundamentals have sharply deteriorated, despite strong underlying demand and market expansion drivers. NVO projects a 5-13% decline in 2026 sales and profits, mainly due to U.S. price compression, yet international growth and robust cash flow persist. Oral Wegovy's rapid adoption and Medicare coverage expansion present significant tailwinds, offsetting recent clinical and pricing setbacks.

Altimmune and Novo Nordisk have encountered some headwinds in recent years. Both could rebound, but one of them looks far more likely to do so.

Novo Nordisk lost another head-to-head trial against Eli Lilly. The company is cutting prices on weight-loss drugs in 2026.

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Novo Nordisk: Can't Ignore It At These Valuations (Rating Upgrade)

Expand NYSE: NVO Novo Nordisk Today's Change (-1.11%) $-0.43 Current Price $38.16 Key Data Points Market Cap $130B Day's Range $37.65 - $38.24 52wk Range $37.65 - $91.90 Volume 55M Avg Vol 22M Gross Margin 80.90% Dividend Yield 4.47% Novo Nordisk (NVO 1.11%), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weighed a large Vivtex partnership while watching how competition and margins shape Novo's obesity and diabetes franchise.

The big news around Novo Nordisk for the past couple of years has been about GLP-1 drugs. Looking back in its history, however, the longer-term story is about its role in treating diabetes.

But beneath the selloff, something unusual has emerged.

LOS ANGELES, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Novo Nordisk A/S (NYSE: NVO) shares are down during Wednesday's premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027, adding pressure as broader markets edged lower.